

**To:** Burke, Thomas[Burke.Thomas@epa.gov]  
**Cc:** Smith, Kelley[Smith.Kelley@epa.gov]; Deener, Kathleen[Deener.Kathleen@epa.gov]  
**From:** Bahadori, Tina  
**Sent:** Fri 6/12/2015 10:30:10 PM  
**Subject:** Some reading and talking bullets  
[ToxCast News ehp.123-A20.alt.pdf](#)  
[McPartland ehp.1408601.alt.pdf](#)  
[IARC Monographs overview for OPP v2.pdf](#)  
[Lancet news.pdf](#)  
[Post SAP ER model manuscript v11.docx](#)

Tom,

A few elements we discussed yesterday about your time on the agenda:

- I have attached the EHP paper and commentary that precipitated this EDF workshop.
- I think you can easily draw on your own 2011 APHA keynote address, “Toxicogenomics and improving public health.” If memory serves, I bet you can use most of the materials – possibly verbatim.
- I have also attached the overview of the glyphosate IARC monograph. You can see there that IARC is beginning to look at comptox data in their integrated evidence. It happened that for this chemical, the assay coverage was not adequate and therefore they did NOT use the data. But they began the process of developing the framework to incorporate comptox data. The attached Lancet 2 pager has a bit of a story.
- This paper by Robert Tanguay <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871932/pdf/kft235.pdf> is important. He is a current NIEHS grantee, an imminent CSS-NCER grantee, and on the NAS committee on integrating 21<sup>st</sup> century science (Samet chairs).
  - o His zebrafish approaches put the ToxCast data in a systems context and allow linkages to whole organisms...likely an important bridging step to humans.
- The larger message is that the community of environmental public health has worked for too long from a position of ‘ignorance’ in this data poor environment.
  - o Initiatives like ToxCast and Tox21 begin to populate that data landscape.
  - o All the attending biological modeling that is going on also helps to generate and evaluate health hypotheses.
- At EPA and in collaboration with NIEHS, we have begun the process of applying these data to the endocrine disruptor screening program.

- A quick glance at the attached policy pivot paper that was just accepted into ES&T indicates the importance of this shift.
- For the purpose of this policy pivot, the data underwent 'fit-for-purpose' validation.

I think these are all the materials we talked about. I am around this weekend, Monday, and most of Tuesday, if you need to discuss or work further on any of these.

Tina (202-680-8771 cell)